OMER News and Press, Omeros Corporation From 06/09/21

Omeros (OMER) announces preliminary results from the Phase 1 clinical trial of its MASP-3 inhibitor OMS906.The trial is designed as a randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics ((PK)) and pharmacodynamics ((PD)) of intravenous ...

-- Results show good safety and PK/PD profile consistent with low-dose, once-monthly subcutaneous dosing -- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein the...

Omeros (OMER) announces preliminary results from the second cohort of critically ill COVID-19 patients treated with narsoplimab in Bergamo, Italy.Narsoplimab is the company’s lead inhibitor of mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the ...

-- Study Patients Comprise Second Cohort from Bergamo, Italy -- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan...

Gainers: Big Rock Partners Acquisition (BRPA) +86%.Euro Tech Holdings (CLWT) +32%.Urban One (UONE) +28%.Sensei Biotherapeutics (SNSE) +28%.BBQ Holdings (BBQ) +22%.PDS Biotechnology (PDSB) +20%.Advanced Emissions Solutions (ADES) +19%.Progenity (PROG) +18%.Moxian (MOXC) +16%.Precipio (PRP...

Gainers: Precipio (PRPO) +23%, PDS Biotechnology (PDSB) +20%, Sensei Biotherapeutics (SNSE) +18%, Iovance Biotherapeutics (IOVA) +17%, Tyme Technologies (TYME) +12%.Losers: Black Diamond Therapeutics (BDTX) -30%, Aerpio Pharmaceuticals (A...

Omeros (OMER) announces that the U.S. FDA will require additional time to review the Biologics License Application ((BLA)) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.The health regulator has set an action date of October 17, 2...

-- PDUFA Date is October 17, 2021-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting infla...

Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from Omeros’ pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be shared as an oral presentation at t...

Omeros Corp (OMER) Q1 2021 Earnings Conference Call May 10, 2021, 16:30 ET Company Participants Jennifer Williams - Investor Relations Gregory Demopulos - Co-Founder, Chairman, CEO & President Nadia Dac - Chief Commercial Officer Michael Jacobsen - CAO, VP, Finance & Treasurer Steven ...